NEW YORK, NY / ACCESSWIRE / November 10, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Pintec Technology Holdings Limited (NASDAQ:PT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/pintec-technology-holdings-limited-loss-submission-form?prid=10848&wire=1
Lead Plaintiff Deadline: November 30, 2020
This lawsuit is on behalf of shareholders who purchased PT securities pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's October 2018 initial public offering.
Allegations against PT include that: (1) the Company erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) there were material weaknesses in Pintec's internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) as a result of the foregoing, the Company's financial results for fiscal 2017 and 2018 had been misstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Nextcure, Inc. (NASDAQ:NXTC)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/nextcure-inc-loss-submission-form?prid=10848&wire=1
Lead Plaintiff Deadline: November 20, 2020
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
Garrett Motion Inc. (NYSE:GTX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/garrett-motion-inc-loss-submission-form?prid=10848&wire=1
Lead Plaintiff Deadline: November 24, 2020
Class Period: October 1, 2018 - September 18, 2020
Allegations against GTX include that: (1) due to its agreement to indemnify and reimburse Honeywell for certain asbestos-related liability, Garrett was saddled with an unsustainable level of debt; (2) as a result, Garrett had a highly leveraged capital structure that posed significant challenges to its overall strategic and financial flexibility; (3) as a result of the foregoing, Garrett's ability to gain or hold market share was impaired; (4) as a result of the foregoing, the Company was reasonably likely to seek bankruptcy protection; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: